ClinicalTrials.gg
CompletedNCT00320788Updated Mar 1, 2012Results posted

Safety and Efficacy of Repeated Intravitreal Administration of Vascular Endothelial Growth Factor (VEGF) Trap in Patients With Wet Age-Related Macular Degeneration (AMD)

A Phase 2 interventional study of aflibercept injection (VEGF Trap-Eye, BAY86-5321) and aflibercept injection (VEGF Trap-Eye, BAY86-5321) in Macular Degeneration, sponsored by Regeneron Pharmaceuticals. Completed at 18 sites in United States. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2012-03-01.

Sponsored by Regeneron Pharmaceuticals · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
159
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 67 studies testing aflibercept in Macular Degeneration — 3 open to participants now, 6 under way, 2 of them phase 3. aflibercept · Macular Degeneration.

Enrollment
20th of 67
159 · median 54
Started
2006
with 1 other
Phase 2
7 of 67
none open now
Registered
1st of 67
by date
Lead sponsor
10 of 67
Regeneron Pharmaceuticals

Among the 67 studies testing aflibercept in Macular Degeneration, this one is the 20th largest by enrollment, is one of 2 that started in 2006, is one of 7 in phase 2, and was the 1st registered.

Macular Degeneration

1,461 studies on the registry are indexed under Macular Degeneration; 237 are open to participants now.

Browse Macular Degeneration studies →

Open to participants now

3 of the 67 studies testing aflibercept in Macular Degeneration are open now, in 9 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About aflibercept

aflibercept: first FDA approval 2011 (EYLEA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 166 Macular Degeneration studies recruiting now, 117 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 67 studies testing aflibercept in Macular Degeneration, or all of them as a file.
02

Study summary

This study examines the effect of intravitreally administered VEGF Trap in patients with wet AMD.

The purpose of this trial is to assess the ocular and systemic safety and tolerability of repeated intravitreal doses of VEGF Trap in patients with subfoveal choroidal neovascularization (CNV) due to AMD.

Read the detailed description

This is a double masked, prospective, randomized study in which five groups of approximately 30 patients meeting the eligibility criteria will be randomly assigned in a balanced ratio to receive a series of intravitreal (IVT) injections of VEGF Trap into the study eye at 4- or 12 -week intervals over a 12-week period.

After Week 12, patients will be evaluated every 4 weeks. Patients will remain on study or may be eligible to enter a long-term extension study, in which they will continue to receive VEGF Trap.

03

Conditions studied

  • Macular Degeneration

Keywords

  • Neovascular Age-Related Macular Degeneration
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subfoveal CNV secondary to AMD.
  • Central retinal (including lesion) thickness ≥ 300 µm as measured by Optical Coherence Tomography (OCT).
  • Early Treatment of Diabetic Retinopathy Study (ETDRS) best-corrected visual acuity of 73 letters to 34 letters.

Exclusion criteria

Exclusion Criteria:

  • History of any vitreous hemorrhage within 4 weeks prior to Day 1.
  • Aphakia.
  • Significant subfoveal atrophy or scarring.
  • Prior treatment with the following in the study eye:

    • Subfoveal thermal laser therapy.
    • Submacular surgery or other surgical intervention for the treatment of AMD.
    • Extrafoveal laser coagulation treatment within 12 weeks prior to Day 1.
    • Photodynamic therapy (PDT) within 12 weeks prior to Visit 2 (Day 1).
    • Pegaptanib sodium (Macugen) within 8 weeks of Visit 2 (Day 1).
    • Juxtascleral or anecortave acetate within 24 weeks (6 months) prior to Visit 2 (Day 1).
    • Intravitreal administration of triamcinolone acetonide or other steroids within 24 weeks prior to Visit 2 (Day 1), unless no visible residue of drug substance can be seen in the vitreous cavity using indirect ophthalmoscopy.
    • Prior systemic or intravitreal treatment with VEGF Trap, ranibizumab (Lucentis) or bevacizumab (Avastin).
  • Presence of any other condition or laboratory abnormality, which, in the opinion of the Investigator, would interfere with the assessment of disease status/progression or jeopardize the patient's appropriate participation in this Phase II study.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
159 participants (actual)

Study arms

  • Experimental
    aflibercept injection (VEGF Trap-Eye, BAY86-5321) 0.5mg q4

    Biological: aflibercept injection (VEGF Trap-Eye, BAY86-5321)

  • Experimental
    aflibercept injection (VEGF Trap-Eye, BAY86-5321) 0.5mg q12

    Biological: aflibercept injection (VEGF Trap-Eye, BAY86-5321)

  • Experimental
    aflibercept injection (VEGF Trap-Eye, BAY86-5321) 2.0mg q4

    Biological: aflibercept injection (VEGF Trap-Eye, BAY86-5321)

  • Experimental
    aflibercept injection (VEGF Trap-Eye, BAY86-5321) 2.0mg q12

    Biological: aflibercept injection (VEGF Trap-Eye, BAY86-5321)

  • Experimental
    aflibercept injection (VEGF Trap-Eye, BAY86-5321) 4.0mg q12

    Biological: aflibercept injection (VEGF Trap-Eye, BAY86-5321)

Interventions

06

What researchers measure

Primary outcomes

  1. Mean Change of CR/LT From Baseline at Week 12

    CR/LT measured in micrometers (µm); lower individual values represent better outcomes.

    Time frame: Baseline and at Week 12

Secondary outcomes

  1. Mean Percent Change of CR/LT From Baseline at Week 12

    CR/LT measured in micrometers (µm); a more negative percentage represents a better outcome

    Time frame: Baseline and at Week 12

  2. Mean Change in Best Corrected Visual Acuity (BCVA) as Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) From Baseline at Week 12

    Defined study baseline range of ETDRS Best Corrected Visual Acuity of: letter score of 73 to 25 (20/40 to 20/320) in the study eye; a higher score represents better functioning

    Time frame: Baseline and at week 12

  3. Percentage of Participants Who Gained at Least 15 Letters of Vision in the ETDRS Letter Score From Baseline at Week 12

    Defined study baseline range of ETDRS Best Corrected Visual Acuity of: letter score of 73 to 25 (20/40 to 20/320) in the study eye; a higher score represents better functioning

    Time frame: At Week 12

07

Results

Posted Mar 1, 2012
Limitations and caveats
This is a phase 2 study with small numbers of patients per group limiting the conclusions that can be drawn from the resulting data.

Participant flow

The study was conducted at 29 study sites in the United States. Recruitment period: May 2006 to April 2007.

Participant flow — Overall Study
MilestoneAflibercept Injection (VEGF Trap-Eye, BAY86-5321) 0.5mg q4Aflibercept Injection (VEGF Trap-Eye, BAY86-5321) 0.5mg q12Aflibercept Injection (VEGF Trap-Eye, BAY86-5321) 2.0mg q4Aflibercept Injection (VEGF Trap-Eye, BAY86-5321) 2.0mg q12Aflibercept Injection (VEGF Trap-Eye, BAY86-5321) 4.0mg q12
Started3232323231
Participants received treatment (saf)3232313131
Completed2626292726
Not completed66355
Withdrew: Adverse event00010
Withdrew: Death00101
Withdrew: Lost to follow-up02100
Withdrew: Decision by the sponsor11001
Withdrew: Other12111
Withdrew: Physician decision11000
Withdrew: Protocol violation00001
Withdrew: Withdrawal by subject30031

Outcome measures

PrimaryMean Change of CR/LT From Baseline at Week 12

CR/LT measured in micrometers (µm); lower individual values represent better outcomes.

Time frame:
Baseline and at Week 12
Reported as:
Mean · μm
Mean Change of CR/LT From Baseline at Week 12
μmAflibercept Injection 0.5mg q4Aflibercept Injection 0.5mg q12Aflibercept Injection 2.0mg q4Aflibercept Injection 2.0mg q12Aflibercept Injection 4.0mg q12Total
Mean Change of CR/LT From Baseline at Week 12-153.5 ± 113.30-75.6 ± 110.64-169.2 ± 138.46-56.3 ± 133.05-139.8 ± 228.59-118.8 ± 155.31
SecondaryMean Percent Change of CR/LT From Baseline at Week 12

CR/LT measured in micrometers (µm); a more negative percentage represents a better outcome

Time frame:
Baseline and at Week 12
Reported as:
Mean · percent change
Mean Percent Change of CR/LT From Baseline at Week 12
percent changeAflibercept Injection 0.5mg q4Aflibercept Injection 0.5mg q12Aflibercept Injection 2.0mg q4Aflibercept Injection 2.0mg q12Aflibercept Injection 4.0mg q12Total
Mean Percent Change of CR/LT From Baseline at Week 12-32.4 ± 18.92-15.2 ± 22.52-33.2 ± 19.56-10.3 ± 25.49-21.1 ± 31.56-22.5 ± 25.41
SecondaryMean Change in Best Corrected Visual Acuity (BCVA) as Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) From Baseline at Week 12

Defined study baseline range of ETDRS Best Corrected Visual Acuity of: letter score of 73 to 25 (20/40 to 20/320) in the study eye; a higher score represents better functioning

Time frame:
Baseline and at week 12
Reported as:
Mean · letters read
Mean Change in Best Corrected Visual Acuity (BCVA) as Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) From Baseline at Week 12
letters readAflibercept Injection 0.5mg q4Aflibercept Injection 0.5mg q12Aflibercept Injection 2.0mg q4Aflibercept Injection 2.0mg q12Aflibercept Injection 4.0mg q12Total
Mean Change in Best Corrected Visual Acuity (BCVA) as Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) From Baseline at Week 128.8 ± 9.203.8 ± 11.558.3 ± 10.145.2 ± 8.462.6 ± 8.725.7 ± 9.87
SecondaryPercentage of Participants Who Gained at Least 15 Letters of Vision in the ETDRS Letter Score From Baseline at Week 12

Defined study baseline range of ETDRS Best Corrected Visual Acuity of: letter score of 73 to 25 (20/40 to 20/320) in the study eye; a higher score represents better functioning

Time frame:
At Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Who Gained at Least 15 Letters of Vision in the ETDRS Letter Score From Baseline at Week 12
percentage of participantsAflibercept Injection 0.5mg q4Aflibercept Injection 0.5mg q12Aflibercept Injection 2.0mg q4Aflibercept Injection 2.0mg q12Aflibercept Injection 4.0mg q12Total
Percentage of Participants Who Gained at Least 15 Letters of Vision in the ETDRS Letter Score From Baseline at Week 1218.8 ± 021.9 ± 025.8 ± 016.1 ± 09.7 ± 018.5 ± 0
Post-hocMean Change of CR/LT From Baseline at Week 16

CR/LT measured in micrometers (µm); lower individual values represent better outcomes

Time frame:
Baseline and at Week 16
Reported as:
Mean · µm
Mean Change of CR/LT From Baseline at Week 16
µmAflibercept Injection 0.5mg q4Aflibercept Injection 0.5mg q12Aflibercept Injection 2.0mg q4Aflibercept Injection 2.0mg q12Aflibercept Injection 4.0mg q12Total
Mean Change of CR/LT From Baseline at Week 16-163.3 ± 108.13-139.6 ± 126.41-182.7 ± 146.75-107.4 ± 112.22-208.6 ± 202.07-160.2 ± 145.34
Post-hocMean Change in BCVA as Measured by ETDRS From Baseline at Week 16

Defined study baseline range of ETDRS Best Corrected Visual Acuity of: letter score of 73 to 25 (20/40 to 20/320) in the study eye; a higher score represents better functioning

Time frame:
Baseline and at Week 16
Reported as:
Mean · letters read
Mean Change in BCVA as Measured by ETDRS From Baseline at Week 16
letters readAflibercept Injection 0.5mg q4Aflibercept Injection 0.5mg q12Aflibercept Injection 2.0mg q4Aflibercept Injection 2.0mg q12Aflibercept Injection 4.0mg q12Total
Mean Change in BCVA as Measured by ETDRS From Baseline at Week 169.3 ± 9.925.6 ± 12.2410.0 ± 9.764.3 ± 10.013.9 ± 9.926.6 ± 10.60

Adverse events

Collected over Adverse events (AEs) considered related to study treatment were followed until resolution or until the event was considered chronic or stable.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Aflibercept Injection 0.5mg q4———
Aflibercept Injection 0.5mg q12———
Aflibercept Injection 2.0mg q4———
Aflibercept Injection 2.0mg q12———
Aflibercept Injection 4.0mg q12———
Most frequent serious events
Showing 10 of 51
Most frequent serious events
EventAflibercept Injection 0.5mg q4Aflibercept Injection 0.5mg q12Aflibercept Injection 2.0mg q4Aflibercept Injection 2.0mg q12Aflibercept Injection 4.0mg q12
CARDIAC FAILURE CONGESTIVECardiac disorders1/320/322/310/310/31
CORONARY ARTERY DISEASECardiac disorders0/320/322/310/310/31
PNEUMONIAInfections and infestations2/320/322/310/310/31
OSTEOARTHRITISMusculoskeletal and connective tissue disorders0/320/321/310/310/31
SPINAL OSTEOARTHRITISMusculoskeletal and connective tissue disorders0/320/320/311/310/31
METASTASES TO LUNGNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/320/320/311/310/31
PANCREATIC CARCINOMANeoplasms benign, malignant and unspecified (incl cysts and polyps)0/320/321/310/310/31
SQUAMOUS CELL CARCINOMANeoplasms benign, malignant and unspecified (incl cysts and polyps)0/320/321/310/310/31
THYROID NEOPLASMNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/320/320/311/310/31
TRANSITIONAL CELL CARCINOMANeoplasms benign, malignant and unspecified (incl cysts and polyps)0/320/320/311/310/31
Most frequent other events
Showing 10 of 76
Most frequent other events
EventAflibercept Injection 0.5mg q4Aflibercept Injection 0.5mg q12Aflibercept Injection 2.0mg q4Aflibercept Injection 2.0mg q12Aflibercept Injection 4.0mg q12
UPPER RESPIRATORY TRACT INFECTIONInfections and infestations3/321/322/316/313/31
URINARY TRACT INFECTIONInfections and infestations1/323/326/311/312/31
HYPERTENSIONVascular disorders6/321/322/310/313/31
CONSTIPATIONGastrointestinal disorders5/321/320/310/311/31
BRONCHITISInfections and infestations5/322/321/311/313/31
EYE IRRITATIONEye disorders5/320/321/310/311/31
EYE PAINEye disorders5/322/324/311/313/31
VISUAL ACUITY REDUCEDEye disorders1/321/324/311/311/31
VITREOUS DETACHMENTEye disorders4/321/322/313/314/31
SEASONAL ALLERGYImmune system disorders4/322/320/310/311/31

Baseline characteristics

Age Continuous
Age Continuous(years)Aflibercept Injection 0.5mg q4Aflibercept Injection 0.5mg q12Aflibercept Injection 2.0mg q4Aflibercept Injection 2.0mg q12Aflibercept Injection 4.0mg q12Total
Mean79.6 ± 7.5678.5 ± 10.1274.9 ± 7.6379.6 ± 8.9178.3 ± 5.9778.2 ± 8.25
Sex: Female, Male
Sex: Female, Male(Participants)Aflibercept Injection 0.5mg q4Aflibercept Injection 0.5mg q12Aflibercept Injection 2.0mg q4Aflibercept Injection 2.0mg q12Aflibercept Injection 4.0mg q12Total
Female17 ± 025 ± 020 ± 016 ± 020 ± 098
Male15 ± 07 ± 011 ± 015 ± 011 ± 059
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Aflibercept Injection 0.5mg q4Aflibercept Injection 0.5mg q12Aflibercept Injection 2.0mg q4Aflibercept Injection 2.0mg q12Aflibercept Injection 4.0mg q12Total
Hispanic or Latino0 ± 01 ± 02 ± 01 ± 00 ± 04
Not Hispanic or Latino32 ± 031 ± 029 ± 030 ± 031 ± 0153
Unknown or Not Reported0 ± 00 ± 00 ± 00 ± 00 ± 00
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Aflibercept Injection 0.5mg q4Aflibercept Injection 0.5mg q12Aflibercept Injection 2.0mg q4Aflibercept Injection 2.0mg q12Aflibercept Injection 4.0mg q12Total
American Indian or Alaska Native0 ± 00 ± 01 ± 00 ± 00 ± 01
Asian0 ± 00 ± 00 ± 00 ± 00 ± 00
Native Hawaiian or Other Pacific Islander0 ± 00 ± 00 ± 00 ± 00 ± 00
Black or African American0 ± 00 ± 00 ± 00 ± 00 ± 00
White32 ± 032 ± 030 ± 031 ± 031 ± 0156
More than one race0 ± 00 ± 00 ± 00 ± 00 ± 00
Unknown or Not Reported0 ± 00 ± 00 ± 00 ± 00 ± 00
Central Retinal/Lesion Thickness (CR/LT)
Central Retinal/Lesion Thickness (CR/LT)(µm)Aflibercept Injection 0.5mg q4Aflibercept Injection 0.5mg q12Aflibercept Injection 2.0mg q4Aflibercept Injection 2.0mg q12Aflibercept Injection 4.0mg q12Total
Mean442.2 ± 109.81442.6 ± 136.60453.3 ± 143.93447.0 ± 119.11497.5 ± 191.17456.4 ± 142.41
Best Corrected Visual Acuity (BCVA)
Best Corrected Visual Acuity (BCVA)(letters read)Aflibercept Injection 0.5mg q4Aflibercept Injection 0.5mg q12Aflibercept Injection 2.0mg q4Aflibercept Injection 2.0mg q12Aflibercept Injection 4.0mg q12Total
Mean54.1 ± 13.7755.6 ± 11.7557.9 ± 12.0257.2 ± 10.4753.0 ± 14.5255.5 ± 12.57
08

Study locations

18 sites
  • Associated Retina Consultants
    Phoenix, Arizona 85020, United States
  • Retina Centers, PC
    Tucson, Arizona 85704, United States
  • Retina Vitreous Associates Medical Group
    Beverly Hills, California 90211, United States
  • Loma Linda University Health Care
    Loma Linda, California 92354, United States
  • Southeast Retina Center
    Augusta, Georgia 30909, United States
  • University of Chicago
    Chicago, Illinois 60637, United States
  • Midwest Eye Institute
    Indianapolis, Indiana 46280, United States
  • Johns Hopkins Hospital School of Medicine
    Baltimore, Maryland 21287, United States
  • Ophthalmic Consultants of Boston
    Boston, Massachusetts 02114, United States
  • New England Retina Consultants PC
    West Springfield, Massachusetts 10189, United States
  • Charlotte Eye, Ear, Nose & Throat Asssociates
    Charlotte, North Carolina 28210, United States
  • Dean A. McGee Eye Institute
    Oklahoma City, Oklahoma 73104, United States
  • Retina Northwest PC
    Portland, Oregon 97210, United States
  • Retina Diagnostic and Treatment Assoc., LLC
    Philadelphia, Pennsylvania 19107, United States
  • Black Hills Regional Eye Institute
    Rapid City, South Dakota 57701, United States
  • Retina-Vitreous Associates, P.C.
    Nashville, Tennessee 37203, United States
  • Vitreoretinal Consultants Scurlock Tower Texas Medical Center
    Houston, Texas 77030, United States
  • Medical Center Ophthamology
    San Antonio, Texas 78240, United States
09

References and documents

Publications

  • Li E, Donati S, Lindsley KB, Krzystolik MG, Virgili G. Treatment regimens for administration of anti-vascular endothelial growth factor agents for neovascular age-related macular degeneration. Cochrane Database Syst Rev. 2020 May 5;5(5):CD012208. doi: 10.1002/14651858.CD012208.pub2. PubMed 32374423 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2006, a primary completion of Jun 2008 and a completion of Aug 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2012, 3 years 9 months after primary completion. A results delay was requested in Nov 2010.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 28, 2006
First posted
May 3, 2006
Start
Apr 2006
Primary completionActual
Jun 2008
CompletionActual
Aug 2008
Results delay requested
Nov 30, 2010
Results first posted
Mar 1, 2012
Last update
Mar 1, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 1, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00320788
Collaborators
Bayer
Responsible party
Sponsor
First posted
May 3, 2006
Start date
Apr 2006
Primary completion
Jun 2008
Completion
Aug 2008
Results posted
Mar 1, 2012
Last update
Mar 1, 2012

Study contacts

Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aflibercept

Start the discussion